<unk> , sold under the brand name Elocta among others, is a medication for the treatment and prophylaxis of bleeding in people with hemophilia A.<unk>  is a recombinant human coagulation factor VIII, Fc fusion protein (rFVIIIFc). It is produced by recombinant DNA technology in a human embryonic kidney (HEK) cell line. It was approved for medical use in the United States in June 2014, and for use in the European Union in November 2015.
Efmoroctocog alfa
Vonicog alfa
Drotrecogin alfa
Moroctocog alfa
Etelcalcetide
Susoctocog alfa
Damoctocog alfa pegol
Difelikefalin